GlassScriptPhysician profile
Ronald A Iverson
NPI 1265407589
$1,733.35
in general payments reported to CMS, 2019-2025
19 companies · $408 in 2025
The $408 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $54.93 · 2021: $151 · 2022: $206 · 2023: $182 · 2024: $396 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $986.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $985.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $550.38 | 2019-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $253.77 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $249.98 | 2019-2025 | Tepezza |
| Abbott Laboratories | $84.63 | 2021-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $82.35 | 2022-2025 | Mounjaro, Zepbound |
| Tandem Diabetes Care, INC. | $76.45 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $57.70 | 2024 | Gvoke Hypopen |
| Abbvie INC. | $55.93 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $52.41 | 2022 | |
| Astellas Pharma US INC | $43.74 | 2024 | Veozah |
| Sequel Med Tech, LLC | $41.86 | 2025 | Twiist |
| Janssen Pharmaceuticals, INC | $41.29 | 2019-2024 | Xarelto |
| Medtronic, INC. | $32.15 | 2023-2025 | Minimed 780g |
| Sanofi-Aventis U.S. LLC | $27.11 | 2019-2025 | |
| Daiichi Sankyo INC. | $22.37 | 2024 | Injectafer |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $16.32 | 2025 | Arexvy, Shingrix |
| Pfizer INC. | $15.38 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.91 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.62 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Iverson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.